PinX1 serves as a potential prognostic indicator for clear cell renal cell carcinoma and inhibits its invasion and metastasis by suppressing MMP-2 via NF-κB-dependent transcription

Oncotarget

Volumn 6, Issue 25, 2015, Pages 21406-21420

  Li, Hai Long ^a,b   Han, Li ^b   Chen, Hai Rong ^a   Meng, Fei ^b   Liu, Qing Hua ^b   Pan, Zhen Qiang ^b,c   Bai, Jin ^b,c   Zheng, Jun Nian ^a,b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b XUZHOU MEDICAL UNIVERSITY   (China)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Metastasis; MMP 2; NF B; pinX1; Prognostic

Indexed keywords

GELATINASE A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR RELA; MATRIX METALLOPROTEINASE INHIBITOR; MMP2 PROTEIN, HUMAN; PINX1 PROTEIN, HUMAN; RELA PROTEIN, HUMAN; SMALL INTERFERING RNA; TUMOR SUPPRESSOR PROTEIN;

ADULT; ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PROGNOSIS; CELL INVASION; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS INHIBITION; MIGRATION INHIBITION; MOUSE; NONHUMAN; OVERALL SURVIVAL; PINX1 GENE; RENAL CANCER CELL LINE; TISSUE MICROARRAY; TUMOR INVASION; AGED; ANIMAL; BAGG ALBINO MOUSE; CARCINOMA, RENAL CELL; CELL MOTION; CHEMISTRY; COHORT ANALYSIS; CYTOPLASM; DISEASE FREE SURVIVAL; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; LIVER NEOPLASMS; METABOLISM; METASTASIS; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

AGED; ANIMALS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL MOVEMENT; COHORT STUDIES; CYTOPLASM; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE INHIBITORS; MICE; MICE, INBRED BALB C; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELA; TUMOR SUPPRESSOR PROTEINS;

EID: 84940773794     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4011     Document Type: Article

References (56)

1. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA: a cancer journal for clinicians. 2014; 64:104-117.
2. Baldewijns MM, van Vlodrop IJ, Schouten LJ, Soetekouw PM, de Bruine AP, van Engeland M. Genetics and epigenetics of renal cell cancer. Biochimica et biophysica acta. 2008; 1785:133-155.
3. Brugarolas J. Renal-cell carcinoma-molecular pathways and therapies. The New England journal of medicine. 2007; 356:185-187.
4. Cohen HT, McGovern FJ. Renal-cell carcinoma. The New England journal of medicine. 2005; 353:2477-2490.
5. Shay JW, Wright WE. Telomerase: a target for cancer therapeutics. Cancer cell. 2002; 2:257-265.
6. Blackburn EH. Switching and signaling at the telomere. Cell. 2001; 106:661-673.
7. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994; 266:2011-2015.
8. Broccoli D, Young JW, de Lange T. Telomerase activity in normal and malignant hematopoietic cells. Proceedings of the National Academy of Sciences of the United States of America. 1995; 92:9082-9086.
9. Wang J, Xie LY, Allan S, Beach D, Hannon GJ. Myc activates telomerase. Genes & development. 1998; 12:1769-1774.
10. Lin SY, Elledge SJ. Multiple tumor suppressor pathways negatively regulate telomerase. Cell. 2003; 113:881-889.
11. Smogorzewska A, de Lange T. Regulation of telomerase by telomeric proteins. Annual review of biochemistry. 2004; 73:177-208.
12. van Steensel B, de Lange T. Control of telomere length by the human telomeric protein TRF1. Nature. 1997; 385:740-743.
13. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes & development. 2005; 19:2100-2110.
14. Lee TH, Tun-Kyi A, Shi R, Lim J, Soohoo C, Finn G, Balastik M, Pastorino L, Wulf G, Zhou XZ, Lu KP. Essential role of Pin1 in the regulation of TRF1 stability and telomere maintenance. Nature cell biology. 2009; 11:97-105.
15. Zhou XZ, Lu KP. The Pin2/TRF1-interacting protein PinX1 is a potent telomerase inhibitor. Cell. 2001; 107:347-359.
16. Baffa R, Santoro R, Bullrich F, Mandes B, Ishii H, Croce CM. Definition and refinement of chromosome 8p regions of loss of heterozygosity in gastric cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2000; 6:1372-1377.
17. Bova GS, MacGrogan D, Levy A, Pin SS, Bookstein R, Isaacs WB. Physical mapping of chromosome 8p22 markers and their homozygous deletion in a metastatic prostate cancer. Genomics. 1996; 35:46-54.
18. Kishimoto Y, Shiota G, Wada K, Kitano M, Nakamoto K, Kamisaki Y, Suou T, Itoh T, Kawasaki H. Frequent loss in chromosome 8p loci in liver cirrhosis accompanying hepatocellular carcinoma. Journal of cancer research and clinical oncology. 1996; 122:585-589.
19. Zhang B, Bai YX, Ma HH, Feng F, Jin R, Wang ZL, Lin J, Sun SP, Yang P, Wang XX, Huang PT, Huang CF, Peng Y, Chen YC, Kung HF, Huang JJ. Silencing PinX1 compromises telomere length maintenance as well as tumorigenicity in telomerase-positive human cancer cells. Cancer research. 2009; 69:75-83.
20. Zhou XZ, Huang P, Shi R, Lee TH, Lu G, Zhang Z, Bronson R, Lu KP. The telomerase inhibitor PinX1 is a major haploinsufficient tumor suppressor essential for chromosome stability in mice. The Journal of clinical investigation. 2011; 121:1266-1282.
21. Chen G, Da L, Wang H, Xu Y, Chen G, Sun C, Wang L, Zhao J, Zhang F, Feng J, Wang Y, Tiollais P, Li T, Zhao M. HIV-Tat-mediated delivery of an LPTS functional fragment inhibits telomerase activity and tumorigenicity of hepatoma cells. Gastroenterology. 2011; 140:332-343.
22. Zhang L, Jiang Y, Zheng Y, Zeng Y, Yang Z, Huang G, Liu D, Gao M, Shen X, Wu G, Yan X, He F. Selective killing of Burkitt's lymphoma cells by mBAFF-targeted delivery of PinX1. Leukemia. 2011; 25:331-340.
23. Zuo J, Wang DH, Zhang YJ, Liu L, Liu FL, Liu W. Expression and mechanism of PinX1 and telomerase activity in the carcinogenesis of esophageal epithelial cells. Oncology reports. 2013; 30:1823-1831.
24. Ma Y, Wu L, Liu C, Xu L, Li D, Li JC. The correlation of genetic instability of PINX1 gene to clinico-pathological features of gastric cancer in the Chinese population. Journal of cancer research and clinical oncology. 2009; 135:431-437.
25. Cai MY, Zhang B, He WP, Yang GF, Rao HL, Rao ZY, Wu QL, Guan XY, Kung HF, Zeng YX, Xie D. Decreased expression of PinX1 protein is correlated with tumor development and is a new independent poor prognostic factor in ovarian carcinoma. Cancer science. 2010; 101:1543-1549.
26. Lai XF, Shen CX, Wen Z, Qian YH, Yu CS, Wang JQ, Zhong PN, Wang HL. PinX1 regulation of telomerase activity and apoptosis in nasopharyngeal carcinoma cells. Journal of experimental & clinical cancer research: CR. 2012; 31:12.
27. Shi R, Zhao Z, Zhou H, Wei M, Ma WL, Zhou JY, Tan WL. Reduced expression of PinX1 correlates to progressive features in patients with prostate cancer. Cancer cell international. 2014; 14:46.
28. Brooks SA, Lomax-Browne HJ, Carter TM, Kinch CE, Hall DM. Molecular interactions in cancer cell metastasis. Acta histochemica. 2010; 112:3-25.
29. DeClerck YA, Mercurio AM, Stack MS, Chapman HA, Zutter MM, Muschel RJ, Raz A, Matrisian LM, Sloane BF, Noel A, Hendrix MJ, Coussens L, Padarathsingh M. Proteases, extracellular matrix, and cancer: a workshop of the path B study section. The American journal of pathology. 2004; 164:1131-1139.
30. Giannelli G, Erriquez R, Fransvea E, Daniele A, Trerotoli P, Schittulli F, Grano M, Quaranta M, Antonaci S. Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients. International journal of cancer Journal international du cancer. 2004; 109:782-785.
31. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006; 441:431-436.
32. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nature reviews Cancer. 2002; 2:301-310.
33. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature. 1994; 370:61-65.
34. Zhou XZ. PinX1: a sought-after major tumor suppressor at human chromosome 8p23. Oncotarget. 2011; 2:810-819.
35. Lughezzani G, Jeldres C, Isbarn H, Perrotte P, Shariat SF, Sun M, Widmer H, Arjane P, Peloquin F, Pharand D, Patard JJ, Graefen M, Montorsi F, Karakiewicz PI. Tumor size is a determinant of the rate of stage T1 renal cell cancer synchronous metastasis. The Journal of urology. 2009; 182:1287-1293.
36. Karakiewicz PI, Trinh QD, Bhojani N, Bensalah K, Salomon L, de la Taille A, Tostain J, Cindolo L, Altieri V, FicarraV, Schips L, Zigeuner R, Mulders PF, Valeri A, Descotes JL, Mejean A, et al. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: prognostic indicators of disease-specific survival. European urology. 2007; 51:1616-1624.
37. Sun M, Shariat SF, Cheng C, Ficarra V, Murai M, Oudard S, Pantuck AJ, Zigeuner R, Karakiewicz PI. Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. European urology. 2011; 60:644-661.
38. Duffy MJ. The biochemistry of metastasis. Advances in clinical chemistry. 1996; 32:135-166.
39. Price JT, Bonovich MT, Kohn EC. The biochemistry of cancer dissemination. Critical reviews in biochemistry and molecular biology. 1997; 32:175-253.
40. Hujanen ES, Terranova VP. Migration of tumor cells to organ-derived chemoattractants. Cancer research. 1985; 45:3517-3521.
41. Fukuyama R, Ng KP, Cicek M, Kelleher C, Niculaita R, Casey G, Sizemore N. Role of IKK and oscillatory NFkappaB kinetics in MMP-9 gene expression and chemoresistance to 5-fluorouracil in RKO colorectal cancer cells. Molecular carcinogenesis. 2007; 46:402-413.
42. Su Y, Gao L, Teng L, Wang Y, Cui J, Peng S, Fu S. Id1 enhances human ovarian cancer endothelial progenitor cell angiogenesis via PI3K/Akt and NF-kappaB/MMP-2 signaling pathways. Journal of translational medicine. 2013; 11:132.
43. Prakash M, Kale S, Ghosh I, Kundu GC, Datta K. Hyaluronan-binding protein 1 (HABP1/p32/gC1qR) induces melanoma cell migration and tumor growth by NF-kappa B dependent MMP-2 activation through integrin alpha(v)beta(3) interaction. Cellular signalling. 2011; 23:1563-1577.
44. Shih YW, Chien ST, Chen PS, Lee JH, Wu SH, Yin LT. Alpha-mangostin suppresses phorbol 12-myristate 13-acetate-induced MMP-2/MMP-9 expressions via alphavbeta3 integrin/FAK/ERK and NF-kappaB signaling pathway in human lung adenocarcinoma A549 cells. Cell biochemistry and biophysics. 2010; 58:31-44.
45. Wang S, Wu X, Zhang J, Chen Y, Xu J, Xia X, He S, Qiang F, Li A, Shu Y, Roe OD, Li G, Zhou JW. CHIP functions as a novel suppressor of tumour angiogenesis with prognostic significance in human gastric cancer. Gut. 2013; 62:496-508.
46. Wang S, Liao C, Li T, Zhao M. Cloning and characterization of the promoter region of human LPTS/PinX1 gene. Biochimica et biophysica acta. 2004; 1676:261-265.
47. Jay N, Moscicki AB. Human papillomavirus infections in women with HIV disease: prevalence, risk, and management. The AIDS reader. 2000; 10:659-668.
48. Aravindakumar CT, Ceulemans J, De Ley M. Nitric oxide induces Zn2+ release from metallothionein by destroying zinc-sulphur clusters without concomitant formation of S-nitrosothiol. The Biochemical journal. 1999; 344:253-258.
49. Jianfeng D, Feng J, Chaoneng J, Zhongzhou Z, Shaohua G, Qihan W, Liu W, Gang Y, Yi X, Mao Y. Cloning of the correct full length cDNA of NF-kappaB-repressing factor. Molecules and cells. 2003; 16:397-401.
50. Nourbakhsh M, Hauser H. Constitutive silencing of IFN-beta promoter is mediated by NRF (NF-kappaB-repressing factor), a nuclear inhibitor of NF-kappaB. The EMBO journal. 1999; 18:6415-6425.
51. Nourbakhsh M, Oumard A, Schwarzer M, Hauser H. NRF, a nuclear inhibitor of NF-kappaB proteins silencing interferon-beta promoter. European cytokine network. 2000; 11:500-501.
52. Heng DY, Mackenzie MJ, Vaishampayan UN, Bjarnason GA, Knox JJ, Tan MH, Wood L, Wang Y, Kollmannsberger C, North S, Donskov F, Rini BI, Choueiri TK. Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2012; 23:1549-1555.
53. Bai J, Yong HM, Chen FF, Mei PJ, Liu H, Li C, Pan ZQ, Wu YP, Zheng JN. Cullin1 is a novel marker of poor prognosis and a potential therapeutic target in human breast cancer. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2013; 24:2016-2022.
54. Chen F, Bai J, Li W, Mei P, Liu H, Li L, Pan Z, Wu Y, Zheng J. RUNX3 suppresses migration, invasion and angiogenesis of human renal cell carcinoma. PloS one. 2013; 8:e56241.
55. Bai J, Zhang J, Wu J, Shen L, Zeng J, Ding J, Wu Y, Gong Z, Li A, Xu S, Zhou J, Li G. JWA regulates melanoma metastasis by integrin alphaVbeta3 signaling. Oncogene. 2010; 29:1227-1237.
56. Bai J, Mei PJ, Liu H, Li C, Li W, Wu YP, Yu ZQ, Zheng JN. BRG1 expression is increased in human glioma and controls glioma cell proliferation, migration and invasion in vitro. Journal of cancer research and clinical oncology. 2012; 138:991-998.